Incidence and Determinants of Catheter-Related Bladder Spasms Following Transurethral Resection of the Prostate; A Prospective Review of 80 Cases

Main Article Content

Nasir Oyelowo
Abdullahi Sudi
Mudi Awaisu
Musliu Adetola Tolani
Ahmad Tijani Lawal
Muhammed Ahmed
Ahmad Bello
Hussaini Yusuf Maitama

Keywords

TURP, Bladder Spasms, Determinants, Incidence

Abstract

.


Background: Bladder spasms due to involuntary contraction of the bladder occur frequently following Transurethral resection of the prostate (TURP). They may be aggravated by the presence of a catheter, blood clots, preoperative overactive bladder, or preoperative ingestion of bladder stimulants like caffeine. These bladder spams are painful, associated with peri-catheter leakage of urine, increased post-operative bleeding, and often refractory to postoperative analgesia. The incidence and risk factors for the occurrence of bladder spasms following TURP need to be reviewed and validated to ensure adequate patient counseling and possible lifestyle modification before surgery. We conducted a prospective review of the determinants of bladder spasms in our patients following TURP.


Methodology: The study population was patients with benign prostatic obstruction scheduled for TURP between March 2022 and April 2023. Monopolar transurethral resection of the prostate was done using a continuous flow resectoscope. The primary endpoint of the study was occurrences of bladder spasms postoperatively before the trial without a catheter. Pain perception during the spasms was assessed using a visual analog scale. Clinical data were collected and analyzed to determine their association with the occurrence of bladder spasms postoperatively using regression analysis. Sub-group analysis was also done to correlate significant variables with the severity of pain in patients with spasms.


Results: The mean age of the 80 patients reviewed was 66.9 ±8 years. Bladder spasms were seen in 41(51.2%) of the patients. The presence of overactive bladder (OAB) symptoms and the use of bladder stimulants were statistically significant determinants with a p-value of 0.003 and 0.026 respectively. The age of the patient, preoperative indwelling catheter, prostate volume, and resection time were not statistically determinant variables in the occurrence of bladder spasms post-operatively. 61% had severe pains and 39% had mild pains. There was no significant correlation between the presence of OAB or the use of bladder stimulants with the severity of pains in patients with bladder spasms after TURP.


Conclusions: Half of the patients are likely to have bladder spasms after TURP. The risk of having these spasms is higher in patients with preoperative OAB or patients who are exposed to bladder stimulants. The severity of spasms is however independent of these risk factors.

Abstract 47 | PDF Downloads 23 EPUB Downloads 12 HTML Downloads 10

References

[1] Homma Y, Gotoh M, Kawauchi A, et al. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol 2017; 24: 716–729.

[2] Bortnick E, Brown C, Simma-Chiang V, et al. Modern best practice in the management of benign prostatic hyperplasia in the elderly. Ther Adv Urol 2020; 12: 1–11.

[3] Spoolder DAE, Geelhoed JP. Management of bladder spasms in patients with indwelling urinary catheters: A systematic review. Continence 2023; 7: 100713.

[4] Li S, Song L, Ma Y, et al. Tramadol for the treatment of catheter-related bladder discomfort: A randomized controlled trial. BMC Anesthesiol 2018; 18: 1–5.

[5] Peng XF, Lv XG, Xie H, et al. Effectiveness of Solifenacin for Managing of Bladder Spasms in Patients With Urethroplasty. Am J Mens Health 2017; 11: 1580–1587.

[6] Wang X, Yu Q, Michel MC. Editorial: Benign prostatic hyperplasia and overactive bladder: new members of metabolic syndrome. Front Urol 2023; 3: 1–3.

[7] Anger JT, Esinduy CB, Goldman HB, et al. Patterns of medical management of overactive bladder ( OAB ) and benign prostatic hyperplasia ( BPH ) in the United States. Neurourol Urodyn 2018; 213–222.

[8] Noh JW, Yoo KB, Kim KB, et al. Association between lower urinary tract symptoms and cigarette smoking or alcohol drinking. Transl Androl Urol 2020; 9: 312–321.

[9] Berre MLNP. What do we really know about the role of caffeine on urinary tract symptoms ? A scoping review on caffeine consumption and lower urinary tract symptoms in adults. Neurourol Urodyn 2020; 64: 1–17.

[10] Mitobe Y, Yoshioka T, Baba Y, et al. Predictors of Catheter-Related Bladder Discomfort After Surgery: A Literature Review. J Clin Med Res 2023; 15: 208–215.

[11] Su S, Lin J, Liang L, et al. The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis. Med (United States) 2020; 99: 1–6.

[12] Agarwal A, Dhiraaj S, Singhal V, et al. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort : a prospective , randomized , placebo-controlled , double-blind study. Br J Anaesth 2006; 96: 377–380.

[13] Jang EB, Hong SH, Kim KS, et al. Catheter-related bladder discomfort: How can we manage it? Int Neurourol J 2020; 24: 324–331.

[14] Kawahara T, Ito H, Yao M, et al. Impact of smoking habit on overactive bladder symptoms and incontinence in women. Int J Urol 2020; 27: 1078–1086.

[15] Park J, Lee H, Kim Y, et al. Effectiveness of Fluid and Caffeine Modifications on Symptoms in Adults with Overactive Bladder: A Systematic Review. Int Neurourol J 2023; 27: 23–35.

[16] Burgio KL, Newman DK, Rosenberg MT, et al. Impact of behaviour and lifestyle on bladder health. Int J Clin Pract 2013; 67: 495–504.

[17] Li J, Liao R. Prevention of catheter-related bladder discomfort – pudendal nerve block with ropivacaine versus intravenous tramadol : study protocol for a randomized controlled trial. Trials 2016; 1–6.

[18] Sipal T, Akdere H. The relation between the storage symptoms before and after transurethral resection of the prostate , analysis of the risk factors and the prevention of the symptoms with solifenacin. Int Braz J Urol 2020; 46: 575–584.

Most read articles by the same author(s)